Fig. 6: Protective efficacy against SARS-CoV-2 challenge in cynomolgus macaques. | Cell Discovery

Fig. 6: Protective efficacy against SARS-CoV-2 challenge in cynomolgus macaques.

From: CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity

Fig. 6

a Schematic diagram of immunization, SARS-CoV-2 challenge, sample collection, and detection in cynomolgus monkeys. Cynomolgus monkeys (n = 2) were challenged with a SARS-CoV-2 virus dose of 1 × 107 TCID50 (20% nostril and 80% trachea) 14 days after a booster immunization on day 79. Nasal and throat swabs were collected 1, 3, 5, and 7 days after the challenge. The viral load in the lung tissues was determined seven days after the challenge. b Viral load detection for nasal swab samples during the challenge. c Viral load detection for throat swab samples during the challenge. d Viral load detection for left and right lung lubes after challenge.

Back to article page